Binyan Lin

634 total citations
9 papers, 456 citations indexed

About

Binyan Lin is a scholar working on Molecular Biology, Pharmacology and Cell Biology. According to data from OpenAlex, Binyan Lin has authored 9 papers receiving a total of 456 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 3 papers in Pharmacology and 3 papers in Cell Biology. Recurrent topics in Binyan Lin's work include Angiogenesis and VEGF in Cancer (4 papers), Axon Guidance and Neuronal Signaling (2 papers) and Chemokine receptors and signaling (2 papers). Binyan Lin is often cited by papers focused on Angiogenesis and VEGF in Cancer (4 papers), Axon Guidance and Neuronal Signaling (2 papers) and Chemokine receptors and signaling (2 papers). Binyan Lin collaborates with scholars based in China and United States. Binyan Lin's co-authors include Na Lu, Dawei Yang, Xiuming Song, Kai Zhao, Qinglong Guo, Zhiyu Li, Dongsheng Bai, Chuyue Pan, Haiyan Chen and Renxiang Tan and has published in prestigious journals such as Oncogene, Gene and Journal of Cellular Physiology.

In The Last Decade

Binyan Lin

9 papers receiving 450 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Binyan Lin China 7 241 178 142 75 53 9 456
Fanming Kong China 12 180 0.7× 226 1.3× 113 0.8× 62 0.8× 87 1.6× 61 515
Ke Cheng China 12 151 0.6× 133 0.7× 79 0.6× 84 1.1× 45 0.8× 43 398
Assen Dudov Russia 9 208 0.9× 129 0.7× 217 1.5× 111 1.5× 86 1.6× 16 522
Caroline Chang United States 9 129 0.5× 164 0.9× 127 0.9× 43 0.6× 76 1.4× 14 469
Kefeng Wang China 9 153 0.6× 160 0.9× 122 0.9× 39 0.5× 76 1.4× 17 376
Chengjuan Zhang China 15 174 0.7× 239 1.3× 123 0.9× 48 0.6× 63 1.2× 39 477
Qingqu Guo China 14 247 1.0× 326 1.8× 76 0.5× 92 1.2× 65 1.2× 27 613
Aitor Benedicto Spain 13 183 0.8× 206 1.2× 57 0.4× 54 0.7× 117 2.2× 26 579
Lingyu Tian China 8 150 0.6× 169 0.9× 116 0.8× 86 1.1× 91 1.7× 10 491

Countries citing papers authored by Binyan Lin

Since Specialization
Citations

This map shows the geographic impact of Binyan Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Binyan Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Binyan Lin more than expected).

Fields of papers citing papers by Binyan Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Binyan Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Binyan Lin. The network helps show where Binyan Lin may publish in the future.

Co-authorship network of co-authors of Binyan Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Binyan Lin. A scholar is included among the top collaborators of Binyan Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Binyan Lin. Binyan Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
1.
Lin, Binyan, Xueyan Zhang, J.‐M. Yang, et al.. (2024). Gambogic acid impairs the maintenance and therapeutic resistance of glioma stem cells by targeting B-cell-specific Moloney leukemia virus insert site 1. Phytomedicine. 135. 156070–156070. 5 indexed citations
2.
Zhang, Junzhi, et al.. (2024). Baitouweng decoction alleviates ulcerative colitis by regulating tryptophan metabolism through DOPA decarboxylase promotion. Frontiers in Pharmacology. 15. 1423307–1423307. 5 indexed citations
3.
Lin, Binyan, et al.. (2020). CRMP2 is a therapeutic target that suppresses the aggressiveness of breast cancer cells by stabilizing RECK. Oncogene. 39(37). 6024–6040. 16 indexed citations
4.
Zhao, Yue, Qinglong Guo, Qin Zhu, et al.. (2019). Flavonoid VI-16 protects against DSS-induced colitis by inhibiting Txnip-dependent NLRP3 inflammasome activation in macrophages via reducing oxidative stress. Mucosal Immunology. 12(5). 1150–1163. 62 indexed citations
5.
Lin, Binyan, Kai Zhao, Dawei Yang, et al.. (2018). Wogonoside impedes the progression of acute myeloid leukemia through inhibiting bone marrow angiogenesis. Journal of Cellular Physiology. 234(2). 1913–1924. 11 indexed citations
6.
Lin, Binyan, et al.. (2018). Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1. Gene. 654. 77–86. 289 indexed citations
7.
Zhao, Kai, Yuyuan Yao, Binyan Lin, et al.. (2018). LYG-202 inhibits activation of endothelial cells and angiogenesis through CXCL12/CXCR7 pathway in breast cancer. Carcinogenesis. 39(4). 588–600. 27 indexed citations
8.
Zhao, Kai, Yang Yuan, Binyan Lin, et al.. (2017). LW-215, a newly synthesized flavonoid, exhibits potent anti-angiogenic activity in vitro and in vivo. Gene. 642. 533–541. 23 indexed citations
9.
Zhao, Kai, Xiaorui Li, Binyan Lin, et al.. (2017). Oroxyloside inhibits angiogenesis through suppressing internalization of VEGFR2/Flk‐1 in endothelial cells. Journal of Cellular Physiology. 233(4). 3454–3464. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026